NOT FOR DISTRIBUTION
Header cover image

Market Cap

US$821.7m

Last Updated

2021/05/07 22:03 UTC

Data Sources

Company Financials

Executive Summary

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. More Details

Rewards

Trading at 54.2% below our estimate of its fair value

Earnings have grown 30.2% per year over the past 5 years

Risk Analysis

No risks detected for CXRX.F from our risk checks.


Snowflake Analysis

Mediocre balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has ADVANZ PHARMA's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CXRX.F is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 2% a week.

Volatility Over Time: CXRX.F's weekly volatility has decreased from 36% to 2% over the past year.


Market Performance


7 Day Return

-0.6%

CXRX.F

2.7%

US Pharmaceuticals

-0.3%

US Market


1 Year Return

387.0%

CXRX.F

12.1%

US Pharmaceuticals

50.2%

US Market

Return vs Industry: CXRX.F exceeded the US Pharmaceuticals industry which returned 11.4% over the past year.

Return vs Market: CXRX.F exceeded the US Market which returned 51.8% over the past year.


Shareholder returns

CXRX.FIndustryMarket
7 Day-0.6%2.7%-0.3%
30 Day-0.9%3.8%2.2%
90 Day2.5%1.4%3.8%
1 Year387.0%387.0%16.0%12.1%52.7%50.2%
3 Year-81.0%-81.0%34.5%24.1%63.4%53.1%
5 Year-99.8%-99.8%49.0%30.6%129.6%104.0%

Long-Term Price Volatility Vs. Market

How volatile is ADVANZ PHARMA's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is ADVANZ PHARMA undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CXRX.F ($16.8) is trading below our estimate of fair value ($36.72)

Significantly Below Fair Value: CXRX.F is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CXRX.F is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CXRX.F is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CXRX.F's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CXRX.F is overvalued based on its PB Ratio (108.3x) compared to the US Pharmaceuticals industry average (3.6x).


Future Growth

How is ADVANZ PHARMA forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

14.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as ADVANZ PHARMA has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has ADVANZ PHARMA performed over the past 5 years?

30.2%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CXRX.F is currently unprofitable.

Growing Profit Margin: CXRX.F is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CXRX.F is unprofitable, but has reduced losses over the past 5 years at a rate of 30.2% per year.

Accelerating Growth: Unable to compare CXRX.F's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CXRX.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (9.6%).


Return on Equity

High ROE: CXRX.F has a negative Return on Equity (-986.79%), as it is currently unprofitable.


Financial Health

How is ADVANZ PHARMA's financial position?


Financial Position Analysis

Short Term Liabilities: CXRX.F's short term assets ($449.5M) exceed its short term liabilities ($210.1M).

Long Term Liabilities: CXRX.F's short term assets ($449.5M) do not cover its long term liabilities ($1.4B).


Debt to Equity History and Analysis

Debt Level: CXRX.F's debt to equity ratio (17459%) is considered high.

Reducing Debt: CXRX.F's debt to equity ratio has increased from 287.4% to 17459% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable CXRX.F has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: CXRX.F is unprofitable but has sufficient cash runway for more than 3 years, even with free cash flow being positive and shrinking by 3.8% per year.


Dividend

What is ADVANZ PHARMA current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CXRX.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CXRX.F's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CXRX.F's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CXRX.F's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: CXRX.F is not paying a notable dividend for the US market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CXRX.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Graeme Duncan (45 yo)

3yrs

Tenure

US$1,615,729

Compensation

Mr. Graeme Neville Duncan has served as a Chief Executive Officer at ADVANZ PHARMA Corp. since June 26, 2018 and has served as its Director since 2018. He serves as Executive Director of ADVANZ PHARMA Corp...


CEO Compensation Analysis

Compensation vs Market: Graeme's total compensation ($USD1.62M) is below average for companies of similar size in the US market ($USD2.34M).

Compensation vs Earnings: Graeme's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CXRX.F's management team is considered experienced (2.9 years average tenure).


Board Members

Experienced Board: CXRX.F's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

ADVANZ PHARMA Corp. Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: ADVANZ PHARMA Corp. Limited
  • Ticker: CXRX.F
  • Exchange: OTCPK
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$821.747m
  • Shares outstanding: 48.91m
  • Website: https://www.advanzpharma.com

Number of Employees


Location

  • ADVANZ PHARMA Corp. Limited
  • Capital House
  • 1st Floor
  • London
  • Greater London
  • EC4N 7BL
  • United Kingdom

Listings


Biography

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segmen...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/07 22:03
End of Day Share Price2021/05/06 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.